Mar 16, 2020 - Health

U.S. volunteer receives first shot of experimental coronavirus vaccine

Moderna has developed the first experimental coronavirus medicine, but an approved treatment is more than a year away. (Photo by David L. Ryan/The Boston Globe via Getty Images)
Moderna has developed the first experimental coronavirus vaccine, but an approved treatment is more than a year away. Photo: David L. Ryan/The Boston Globe via Getty Images

A healthy U.S. volunteer received the first dose of an experimental coronavirus vaccine, a potential defense against the virus if it becomes a long-term threat.

Where it stands: The trial will ultimately give 45 volunteers two doses about 28 days apart in order to test the vaccine's effectiveness in protecting the subjects against COVID-19. If successful, several more trials with larger subject groups will be needed to prove whether there are common side effects.

Context: The vaccine candidate, code-named mRNA-1273, was developed by the National Institutes of Health and Massachusetts-based biotechnology company Moderna Inc.

  • Several other vaccines from researchers and companies around the world are in development.

What to watch: Even if the trial is successful, a vaccine for mass production and distribution worldwide will likely not be available for 12–18 months, said Anthony Fauci, director of the NIH's National Institute of Allergy and Infectious Diseases.

Go deeper